Figure 2.

Ixekizumab competes with IL-17RA binding to immobilized human IL-17A.

Notes: Human IL-17A was immobilized on a Biacore chip surface. Binding of IL-17RA/Fc to immobilized IL-17A was shown as increase in response units upon injection of IL-17RA/Fc (A). Ixekizumab bound to immobilized IL-17A as shown by the increase in response units following injection (B). Upon binding of ixekizumab to IL-17A, IL-17RA/Fc can no longer bind (B).

Abbreviations: IL, interleukin; RU, response units; Resp Diff, the difference in RU between active flow cell and reference flow cell.